trending Market Intelligence /marketintelligence/en/news-insights/trending/mbwvrfopulz8vsaf7mjxbg2 content esgSubNav
In This List

Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

French drugmaker Sanofi secured U.S. antitrust clearance for its $11.6 billion acquisition of Waltham, Mass.-based hemophilia specialist Bioverativ Inc.

The waiting period under the Hart-Scott-Rodino Act related to the deal has expired, which means the transaction has received antitrust clearance.

The acquisition is still subject to other conditions, including the tender of at least a majority of Bioverativ's common stock.

On Feb. 7, Sanofi started a tender offer to buy all of Bioverativ's outstanding shares for $105 apiece in cash. The offer will expire March 7.